Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$1.98−0.18 (-8.33%)
Close on Nov 12, 2026Market cap $24.73MP/E –Yield –
Aligos Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Aligos Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $83.33M, up 21.7% year over year. For fiscal 2025 it was $69.45M, down 1.2% from the year before. The highest annual figure on record is $104.15M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.45M | -1.2% |
| FY2024 | Dec 31, 2024 | $70.27M | -3.8% |
| FY2023 | Dec 31, 2023 | $73.04M | -14.1% |
| FY2022 | Dec 31, 2022 | $85.08M | -18.3% |
| FY2021 | Dec 31, 2021 | $104.15M | +30.4% |
| FY2020 | Dec 31, 2020 | $79.89M | +81.4% |
| FY2019 | Dec 31, 2019 | $44.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.89M | -21.1% |
| Q2 FY2026 | Jun 30, 2026 | $24.05M | +72.1% |
| Q1 FY2026 | Mar 31, 2026 | $23.35M | +61.0% |
| Q4 FY2025 | Dec 31, 2025 | $17.04M | +6.3% |
| Q3 FY2025 | Sep 30, 2025 | $23.94M | +42.7% |
| Q2 FY2025 | Jun 30, 2025 | $13.98M | -33.8% |
| Q1 FY2025 | Mar 31, 2025 | $14.50M | -11.4% |
| Q4 FY2024 | Dec 31, 2024 | $16.03M | -28.0% |
| Q3 FY2024 | Sep 30, 2024 | $16.77M | +5.7% |
| Q2 FY2024 | Jun 30, 2024 | $21.10M | +25.7% |
| Q1 FY2024 | Mar 31, 2024 | $16.37M | -9.8% |
| Q4 FY2023 | Dec 31, 2023 | $22.26M | +16.5% |
| Q3 FY2023 | Sep 30, 2023 | $15.87M | -10.8% |
| Q2 FY2023 | Jun 30, 2023 | $16.78M | +1.6% |
| Q1 FY2023 | Mar 31, 2023 | $18.14M | -42.7% |
| Q4 FY2022 | Dec 31, 2022 | $19.10M | -33.2% |
| Q3 FY2022 | Sep 30, 2022 | $17.79M | -36.8% |
| Q2 FY2022 | Jun 30, 2022 | $16.51M | -32.8% |
| Q1 FY2022 | Mar 31, 2022 | $31.68M | +38.5% |
| Q4 FY2021 | Dec 31, 2021 | $28.60M | +1.8% |
| Q3 FY2021 | Sep 30, 2021 | $28.13M | +62.3% |
| Q2 FY2021 | Jun 30, 2021 | $24.55M | +43.0% |
| Q1 FY2021 | Mar 31, 2021 | $22.87M | +32.2% |
| Q4 FY2020 | Dec 31, 2020 | $28.08M | +87.5% |
| Q3 FY2020 | Sep 30, 2020 | $17.33M | +47.8% |
| Q2 FY2020 | Jun 30, 2020 | $17.18M | – |
| Q1 FY2020 | Mar 31, 2020 | $17.30M | – |
| Q4 FY2019 | Dec 31, 2019 | $14.97M | – |
| Q3 FY2019 | Sep 30, 2019 | $11.73M | – |
See a number that looks wrong?